Live video detailing scores high marks with physicians

Share this article:
According to a new study by Manhattan Research, video detailing is now a viable option for pharma, biotech and device manufacturers. 

Manhattan Research's ePharma Physician v8.0 study found that the majority of physicians who have engaged in online video meetings with a pharma sales rep or cell center report that they are satisfied with the experience. 
The Manhattan Research report includes data and insights around the current state of physician video detailing adoption, demographics, behaviors, and satisfaction; market potential and future interests; delivery models and vendors; and strategic implementation best practices. 

The objective of the analysis is to provide pharmaceutical, biotech and device manufacturers with the market data and analysis for justifying strategic investment in video detailing and adapting and planning for the future of the physician-sales and company rep relationship. 

Monique Levy, senior director of research at Manhattan Research and author of the analysis said that video detailing has finally re-emerged as a viable marketing and service option, prompting manufacturers to take another look at this channel to connect with physicians. 

Levy added that video detailing users are some of the industry's most valuable and tech-savvy customers. 
Levy also said that beyond being highly adept at navigating in a multichannel environment, physicians who use video detailing are much more likely to write a larger volume of scripts and to have a higher weekly patient load than non-users of video detailing.
Share this article:
close

Next Article in Features

Email Newsletters

More in Features

Leadership Exchange: How Do We Get Beyond the Pill?

Leadership Exchange: How Do We Get Beyond the ...

As its focus moves from manufacturing to service, pharma needs to partner with healthcare neophytes as well as established players. James Chase asks six experts to assess the risks and ...

FDA and off-label uses: a balancing act

FDA and off-label uses: a balancing act

FDA's current re-examination of its off-label promotion policies in light of the First Amendment is a delicate balancing act between its rock-solid traditional enforcement posture and a diverse new electronic ...

Read the complete August 2014 Digital Edition

Read the complete August 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.